低剂量厄洛替尼在化疗经治的非小细胞肺癌患
点击下方，收听SCI天天读SCIAprospective,multicentrephaseIItrialoflow-doseerlotinibinnon-smallcelllungcancerpatientswithEGFRmutationspretreatedwithchemotherapy:ThoracicOncologyResearchGroup.BACKGRONDLowdoseerlotinibmaybeaseffectiveasgefitiniborerlotinibatfulldoseinnon-smallcelllungcancer(NSCLC)patientswithactivatingmutationsoftheepidermalgrowthfactorreceptor(EGFR)gene.METHODSPatientswithchemotherapypretreatedNSCLCharbouringEGFRmutationsreceivederlotinibat50mg/duntildiseaseprogressionorunacceptabletoxicities.Thedosewasescalatedtomg/dinpatientsshowingnoresponse(i.e.withoutmajortumourshrinkageaccordingtoResponseEvaluationCriteriainSolidTumours(RECIST))totheinitialdoseduringthefirst4weeks.Theprimaryend-pointwastheobjectiveresponserateatthedoseof50mg/d.RESULTSThirty-fourpatientsfromseveninstituteswereenrolled.Thestudywasclosedearlywhennoresponsewasconfirmedin15patients,excludingthepossibilitythattheprimaryend-pointwouldbemet.Theobjectiveresponseanddiseasecontrolratesatthedoseof50mg/dasdeterminedbyanindependentreview北京中科白癜风医院诈骗曝光治疗白癜风最有效的方法
